

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Jonathan A. Terrett

SERIAL NO.: 10/524,910

EXAMINER: Unassigned

DATE FILED: February 17, 2005

ART UNIT: Unassigned

FOR: PTK7 PROTEIN INVOLVEMENT IN CARCINOMA

EXPRESS MAIL NO.: EV 247182862 US

DATE OF DEPOSIT: APRIL 15, 2005

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BA** through **CE** listed on the attached Form PTO-1449. However, with respect to References **BC**, **BD** & **BF**, please note that due to the size of these references (436, 332, & 461 pages respectively), a CD containing references WO 02/30268; WO 02/102235 and WO 02/099062 in Adobe .pdf format is enclosed in place of a printed copy. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,



David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
201-487-5800

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-040PCT/US
	SERIAL NO.	10/524,910
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan Alexander Terrett
	FILING DATE	February 17, 2005
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
/A.H./	BA	WO 96/37610	11/28/96	PCT			
↓	BB	EP 1191107	3/27/02	EUROPE			Abstract in English attached
	BC	WO 02/30268	4/18/02	PCT			
	BD	WO 02 102235	12/27/02	PCT			
	BE	WO 02 86443	10/31/02	PCT			
↓	BF	WO 02 099062	12/12/02	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/A.H./	CA	Lee, ST, et al., A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes, 1993, Oncogene 8: 3403-3410.
↓	CB	Mossie, K, et al., Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family, 1995, Oncogene 11: 2179-2184.
	CC	Park, SK, et al., Characterization of the Human Full-Length PTK7 cDNA Encoding a Receptor Protein Tyrosine Kinase-Like Molecule Closely Related to Chick KLG ¹ , 1996, J. Biochem., (Tokyo). 119(2): 235-9.
	CD	Easty, DJ, et al., Loss of Expression of Receptor Tyrosine Kinase Family Genes PTK7 and SEK in Metastatic Melanoma, 1997, Int. J. Cancer, 71: 1061-1065.
↓	CE	Forus, A., et al., Microarray-based Analysis of Gene Activity Patterns in Osteosarcoma, 2001, Proc. Amer. Assoc. Cancer Res. Annual, 42: 428.
EXAMINER: /Anne Holleran/		DATE CONSIDERED: 09/26/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./</p>		